Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.21590.
SEER. lung and bronchus cancer, recent trends in SEER age-adjusted incidence rates, 2000–2017. Observed Rates By Subtype, Both Sexes, All Races (includes Hispanic), All Ages, All Stages: National Cancer Institute; 2020.
Jin X, Zhao X, Liu X, Han K, Lu G, Zhang Y. Non-small cell lung cancer in young patients: an analysis of clinical, pathologic and TNM stage characteristics compared to the elderly. Risk Manag Healthc Policy. 2020;13:1301–7. https://doi.org/10.2147/RMHP.S264274.
Article PubMed PubMed Central Google Scholar
Citak N, Guglielmetti L, Aksoy Y, Isgorucu O, Metin M, Sayar A, et al. Is there a prognostic difference between stage IIIA subgroups in lung cancer? Ann Thorac Surg. 2020. https://doi.org/10.1016/j.athoracsur.2020.10.033.
Smit MA, Philipsen MW, Postmus PE, Putter H, Tollenaar RA, Cohen D, et al. The prognostic value of the tumor-stroma ratio in squamous cell lung cancer, a cohort study. Cancer Treat Res Commun. 2020;25: 100247. https://doi.org/10.1016/j.ctarc.2020.100247.
Liu L, Shi M, Wang Z, Lu H, Li C, Tao Y, et al. A molecular and staging model predicts survival in patients with resected non-small cell lung cancer. BMC Cancer. 2018;18:966. https://doi.org/10.1186/s12885-018-4881-9.
CAS Article PubMed PubMed Central Google Scholar
Ruiz-Cordero R, Ma J, Khanna A, Lyons G, Rinsurongkawong W, Bassett R, et al. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer. 2020;20:83. https://doi.org/10.1186/s12885-020-6579-z.
CAS Article PubMed PubMed Central Google Scholar
Lu C, Bera K, Wang X, Prasanna P, Xu J, Janowczyk A, et al. A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study. Lancet Digit Health. 2020;2:e594–606. https://doi.org/10.1016/s2589-7500(20)30225-9.
Article PubMed PubMed Central Google Scholar
Reck M, Heigener DF, Mok T, Soria J-C, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382:709–19.
Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, June-Key Chung E, Kim E, Lee DS. Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis. Euro J Nucl Med Mol Imaging. 2015;42(2):241–51. https://doi.org/10.1007/s00259-014-2903-7.
Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European lung cancer working party for the IASLC lung cancer staging project. J Thorac Oncol. 2008;3:6–12.
Na KJ, Choi H. Tumor metabolic features identified by (18)F-FDG PET correlate with gene networks of immune cell microenvironment in head and neck cancer. J Nucl Med. 2018;59:31–7. https://doi.org/10.2967/jnumed.117.194217.
CAS Article PubMed Google Scholar
Cho SY, Lipson EJ, Im H-J, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point <sup>18</sup>F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58:1421–8. https://doi.org/10.2967/jnumed.116.188839.
CAS Article PubMed PubMed Central Google Scholar
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9.
Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018;24:978–85.
Bremnes RM, Busund L-T, Kilvær TL, Andersen S, Richardsen E, Paulsen EE, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol. 2016;11:789–800. https://doi.org/10.1016/j.jtho.2016.01.015.
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–7. https://doi.org/10.1038/nature06309.
CAS Article PubMed Google Scholar
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70. https://doi.org/10.1126/science.1203486.
CAS Article PubMed Google Scholar
Choi J, Gim JA, Oh C, Ha S, Lee H, Choi H, et al. Association of metabolic and genetic heterogeneity in head and neck squamous cell carcinoma with prognostic implications: integration of FDG PET and genomic analysis. EJNMMI Res. 2019;9:97. https://doi.org/10.1186/s13550-019-0563-0.
CAS Article PubMed PubMed Central Google Scholar
Geng Y, Shao Y, He W, Hu W, Xu Y, Chen J, et al. Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis. Cell Physiol Biochem. 2015;37:1560–71. https://doi.org/10.1159/000438523.
CAS Article PubMed Google Scholar
Chen B, Li H, Liu C, Xiang X, Wang S, Wu A, et al. Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: a meta-analysis. PLoS ONE. 2020;15: e0242173. https://doi.org/10.1371/journal.pone.0242173.
CAS Article PubMed PubMed Central Google Scholar
Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17:e542–51. https://doi.org/10.1016/S1470-2045(16)30406-5.
CAS Article PubMed PubMed Central Google Scholar
Bakr S, Gevaert O, Echegaray S, Ayers K, Zhou M, Shafiq M, et al. A radiogenomic dataset of non-small cell lung cancer. Sci Data. 2018;5: 180202. https://doi.org/10.1038/sdata.2018.202.
CAS Article PubMed PubMed Central Google Scholar
Wang C, Zhao K, Shanliang H, Huang Y, Ma L, Li M, Song Y. The PET-derived tumor-to-liver standard uptake ratio (SUVTLR) is superior to tumor SUVmax in predicting tumor response and survival after chemoradiotherapy in patients with locally advanced esophageal cancer. Front Oncol. 2020. https://doi.org/10.3389/fonc.2020.01630.
Article PubMed PubMed Central Google Scholar
de Mestier L, Armani M, Cros J, Hentic O, Rebours V, Cadiot G, et al. Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors. Dig Liver Dis. 2019;51:1720–4. https://doi.org/10.1016/j.dld.2019.06.022.
CAS Article PubMed Google Scholar
Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, Ryan Miller C, Socinski MA, Parsons AM, Thorne LB, Haithcock BE, Veeramachaneni NK, Funkhouser WK, Randell SH, Bernard PS, Perou CM, Neil Hayes D. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS ONE. 2012;7(5):e36530. https://doi.org/10.1371/journal.pone.0036530.
CAS Article PubMed PubMed Central Google Scholar
Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782–95.
Narayanan S, Kawaguchi T, Yan L, Peng X, Qi Q, Takabe K. Cytolytic activity score to assess anticancer immunity in colorectal cancer. Ann Surg Oncol. 2018;25:2323–31.
Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50. https://doi.org/10.1038/nature13385.
Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol. 2006;24:5079–90.
Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32:810–27. https://doi.org/10.1097/PAS.0b013e31815cb162.
Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M. Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape. J Thorac Oncol. 2017;12:943–53. https://doi.org/10.1016/j.jtho.2017.03.010.
Article PubMed PubMed Central Google Scholar
Choi H, Na KJJT. Integrative analysis of imaging and transcriptomic data of the immune landscape associated with tumor metabolism in lung adenocarcinoma: clinical and prognostic implications. Theranostics. 2018;8:1956.
Halvorsen AR, Ragle Aure M, Õjlert ÅK, Brustugun OT, Solberg S, Nebdal D, et al. Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC. Mol Oncol. 2019;13:2604–15. https://doi.org/10.1002/1878-0261.12571.
CAS Article PubMed PubMed Central Google Scholar
Takamochi K, Mogushi K, Kawaji H, Imashimizu K, Fukui M, Oh S, et al. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. PLoS ONE. 2017;12: e0175622. https://doi.org/10.1371/journal.pone.0175622.
CAS Article PubMed PubMed Central Google Scholar
Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M. Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape. J Thorac Oncol. 2017;12:943–53.
Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43:1954–61.
留言 (0)